Trial Profile
A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2013
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours; Glioma; Haematological malignancies; Myeloproliferative disorders; Solid tumours
- Focus Adverse reactions; Biomarker
- 04 Mar 2010 New trial record